Swedish Orphan Biovitrum
Clinical trials sponsored by Swedish Orphan Biovitrum, explained in plain language.
-
Real-World test: can a targeted drug keep PNH in check for years?
Disease control Recruiting nowThis study follows about 200 adults with paroxysmal nocturnal hemoglobinuria (PNH) who are taking pegcetacoplan (Aspaveli/Empaveli) as part of their routine care. Researchers will track blood markers, symptoms, and side effects for up to 3 years to see how well the drug works out…
Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Jul 01, 2026 22:00 UTC
-
New study tracks Real-World impact of hemophilia drug on joint health
Disease control Recruiting nowThis study follows 250 people with hemophilia A who are taking efanesoctocog alfa to prevent bleeding. Researchers want to see how well it protects joints from bleeds over time in everyday life. Participants will be observed for several years to track bleeding rates and treatment…
Phase: PHASE4 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Jul 01, 2026 22:00 UTC
-
New clotting factor offers continued bleeding control for hemophilia a patients
Disease control Recruiting nowThis study gives people with moderate or severe hemophilia A who finished a previous trial continued access to the drug efanesoctocog alfa. The drug is a lab-made clotting factor that helps prevent bleeding episodes. Researchers will monitor safety and how well it controls bleedi…
Phase: PHASE3 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for rare inflammatory disease: pacritinib trial begins
Disease control Recruiting nowThis study tests a drug called pacritinib for people with VEXAS syndrome, a rare genetic disease that causes severe inflammation. About 78 adults will receive either the drug or a placebo to see if it controls symptoms and reduces flare-ups. The goal is to find a safe and effecti…
Phase: PHASE2 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC